A cure for acid flashbacks
Ehave Announces MetaHealthU Will Enter The Market With A Focus On HPPD Ehave Inc. (EHVVF)
April 19, 2022
Ehave Announces MetaHealthU Will Enter The Market With A Focus On HPPD Ehave Inc. (EHVVF)
Magic mushroom compound increases brain connectivity in people with depression “For the first time we
Field Trip Health Ltd. Granted US Patent Covering Novel Psychedelic Molecule FT-104 Field Trip Health
MDMA-assisted therapy significantly reduces eating disorder symptoms in a randomized placebo-controlled trial of adults with
Ibogaine blocks some of the rewarding effects of alcohol in rodent model of addictive behavior
Repeated lysergic acid diethylamide (LSD) reverses stress-induced anxiety-like behavior, cortical synaptogenesis deficits and serotonergic neurotransmission
Tasmanian ketamine study to treat chronic pain patients About 60% of patients with chronic pain
Psilocybin safer to take with psychiatric medications than MDMA, researchers say An analysis of 40 publications found
Small Pharma Expands Potential of Commercial Portfolio with DMT-based Psychedelic Assets After finding its DMT
Novamind to Conduct Phase II Psilocybin Trial for Major Depressive Disorder Novamind (NM) began a
Incannex Executes License Agreement with Monash University to Develop a Combination Treatment Using Virtual Reality
MINDCURE Achieves Key Development Milestone for Novel Ibogaine Program Tripping on ibogaine can last over
MindMed Announces Publication of Study Comparing the Acute Effects of Lysergic Acid Diethylamide and Psilocybin
World’s First clinical trial for DMT-assisted therapy in Major Depressive Disorder Shows Consistent Quality of
PharmaDrug Receives Positive Results for DMT-Analogue Program to Treat Glaucoma Glaucoma can cause irreversible vision
Recruitment for an upcoming trial – Psilocybin as a Treatment for Anorexia Nervosa: A Pilot
Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules One of the few concerns
Healing my worth: Sarah’s story Despite having a supportive family and a healthy lifestyle, Sarah
Psychedelic therapy for depression still effective one year later Johns Hopkins researchers followed up with
Nova Mentis Study Confirms Oral Microdose Psilocybin Treatment of Autism This week, Nova Mentis (NOVA)
Field Trip Health Ltd. Reports Third Fiscal Quarter 2022 Financial Results and Provides Business Update
Cybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the
Fish on acid? Microdosing zebrafish with LSD shows its potential benefits for humans New research suggests
PharmaTher Granted FDA Orphan Drug Designation for Ketamine to Treat Status Epilepticus PharmaTher (PHRM) is